肿瘤坏死因子α
细胞因子
癌症研究
体内
细胞凋亡
医学
纳米技术
化学
生物
免疫学
材料科学
生物技术
生物化学
作者
Hojjat Alizadeh Zeinabad,Éva Szegezdi
出处
期刊:Cancers
[MDPI AG]
日期:2022-10-19
卷期号:14 (20): 5125-5125
被引量:13
标识
DOI:10.3390/cancers14205125
摘要
The death ligand tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF cytokine superfamily, has long been recognized for its potential as a cancer therapeutic due to its low toxicity against normal cells. However, its translation into a therapeutic molecule has not been successful to date, due to its short in vivo half-life associated with insufficient tumor accumulation and resistance of tumor cells to TRAIL-induced killing. Nanotechnology has the capacity to offer solutions to these limitations. This review provides a perspective and a critical assessment of the most promising approaches to realize TRAIL's potential as an anticancer therapeutic, including the development of fusion constructs, encapsulation, nanoparticle functionalization and tumor-targeting, and discusses the current challenges and future perspectives.
科研通智能强力驱动
Strongly Powered by AbleSci AI